Steris Corporation is an American Irish-domiciled medical equipment company specializing in sterilization and surgical products for the US healthcare system.
| Revenue (TTM) | $5.94B |
| Gross Profit (TTM) | $2.63B |
| EBITDA | $1.60B |
| Operating Margin | 20.00% |
| Return on Equity | 11.40% |
| Return on Assets | 6.65% |
| Revenue/Share (TTM) | $60.45 |
| Book Value | $73.45 |
| Price-to-Book | 2.96 |
| Price-to-Sales (TTM) | 3.78 |
| EV/Revenue | 3.863 |
| EV/EBITDA | 14.38 |
| Quarterly Earnings Growth (YoY) | 52.20% |
| Quarterly Revenue Growth (YoY) | 7.30% |
| Shares Outstanding | $97.46M |
| Float | $97.18M |
| % Insiders | 0.31% |
| % Institutions | 100.64% |
Volatility is currently expanding
STE is expected to deliver fiscal first-quarter revenue and EPS growth, driven by strength in Healthcare, continued momentum in AST, and healthy demand in Life Sciences.
DUBLIN, IRELAND, July 27, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2027 first quarter results at 9:00 a.m. ET on August 6, 2026. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.
Steris provides infection prevention products and sterilization services to medical clientele (such as hospitals, outpatient surgery centers, and pharmaceutical companies). Steris has increased its dividend for 21 consecutive years. The 10-year dividend growth rate of 9.6% is strong, but more recent dividend raises have actually been over 10%. STE has a great financial position. Its long-term debt/equity ratio is 0.3, while the interest coverage ratio is over 18.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Steris (STE) reported earnings 30 days ago. What's next for the stock?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
STERIS' Healthcare and AST segments post solid gains and milestones, but FX volatility, tariffs and global macro pressures threaten earnings variability.
STERIS NYSE: STE reported a stronger fiscal 2026 overall despite a lighter fourth quarter, with executives pointing to record annual revenue, resilient procedure demand and continued pricing gains, while also outlining expectations for mid- to high-single-digit growth in fiscal 2027.
STERIS posts Q4 adjusted EPS of $2.83 and revenues of $1.59 billion, both slight misses; shares dip after hours despite broad growth and FY27 guidance.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on STE and any ticker you trade — then tracks every position and per-strategy win rate.
